Advanced Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook
Thelansis’s “Advanced Gastrointestinal
Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Advanced
Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Gastrointestinal Stromal
Tumors (GISTs) Overview
Gastrointestinal
stromal tumors (GISTs) represent 0.1–0.3% of gastrointestinal malignant
neoplasms and are primarily located within the mesenchymal tissue of the
gastrointestinal tract. These tumors can manifest at any age, with a median
patient age of 60–65 years. Clinically, GISTs often present with symptoms such
as gastrointestinal bleeding, anemia, and abdominal pain. The stomach is the
most common site of occurrence, accounting for approximately 50–60% of cases,
followed by the small intestine (20–30%) and, less frequently, the colon and
rectum (5%) and the esophagus (<1%). Metastatic disease is identified in
approximately 15% of patients at the time of diagnosis. Before the advent of
targeted therapies, the management of GISTs was challenging due to their poor
response to conventional chemotherapy and radiation, making surgical resection
the primary therapeutic option. However, many patients who initially undergo
surgery for GISTs eventually experience disease recurrence.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment